Trump may be mystery patient in odd case of 79yo getting experimental obesity drug
A public notice regarding a 79-year-old patient receiving experimental obesity drug retatrutide through a 'compassionate use' program has sparked speculation that the patient is President Donald Trump. The drug, developed by Eli Lilly, is currently in late-stage trials and has shown significant weight-loss results.
Why it matters
The intersection of high-profile political figures and experimental medical treatments raises questions about transparency and access to healthcare.
Special access Trump may be mystery patient in odd case of 79yo getting experimental obesity drug Public notice of a single compassionate use case is odd in every way.
The framing focuses on the 'odd' nature of the case and links it to the President, which is a common angle in critical political reporting.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in